Amanote Research
Register
Sign In
Cost-Effectiveness of Transfusing Virus-Inactivatedplasma Instead of Standard Plasma
Transfusion
- United Kingdom
doi 10.1046/j.1537-2995.1999.39050479.x
Full Text
Open PDF
Abstract
Available in
full text
Categories
Allergy
Immunology
Hematology
Date
May 1, 1999
Authors
A. Pereira
Publisher
Wiley
Related search
Cost Effectiveness of ASHRAE Standard 90.1-2013 for the State of Utah
Cost Effectiveness of ASHRAE Standard 90.1-2013 for the State of Nevada
Pharmacoeconomics of Innovations or Innovation in Pharmacoeconomics: A “Relative Value” Analysis Instead of a “Cost-Effectiveness” Analysis?
Pharmacoeconomics: theory and practice
Cost Effectiveness of ASHRAE Standard 90.1-2013 for the State of Maine
Cost Effectiveness of ASHRAE Standard 90.1-2013 for the State of North Dakota
Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings Without Virological Monitoring
PLoS ONE
Multidisciplinary
Estimating the Cost-Effectiveness of Belimumab Versus Standard Care for Sle Patients in Hong Kong
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Lacosamide Compared With Standard of Antiepileptic Care Based on Clinical Practice Data
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Population Cost-Effectiveness of Weight Watchers With General Practitioner Referral Compared With Standard Care
Obesity
Nutrition
Endocrinology
Dietetics
Medicine
Metabolism
Diabetes
